ArticleNutrients2022
Composition of Maternal Circulating Short-Chain Fatty Acids in Gestational Diabetes Mellitus and Their Associations with Placental Metabolism.
Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Gut microbiota during pregnancy: a bibliometric analysis of global research trends and collaborative networks.Frontiers in microbiology · 2025Pooled it
- Dietary fiber supplementation during late gestation affects steroidogenesis, antioxidant capacity, gut microbiota and placental metabolomics of Rongchang sows.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2026Article
- Maternal and infant gut microbiome.iMeta · 2026Review
- Susceptibility of the Placenta and Fetal Brain to Maternal Probiotic Supplementation.Microorganisms · 2026Article
- Towards microbiome-informed strategies for predicting and preventing pregnancy complications.Reproduction & fertility · 2026Review
- Microbiome, Epigenetics, and Nutritional Factors in Shaping Perinatal Pregnancy Outcomes.International journal of molecular sciences · 2026Review
- Gut microbiota contributes to gestational diabetes mellitus by interfering with bile acid metabolism and resistin.Frontiers in cellular and infection microbiology · 2026Article
- The interplay between gut microbiota and gestational diabetes mellitus: mechanisms, characteristics, and intervention strategies.Frontiers in microbiology · 2026Review
- Gut-placenta axis: gut microbiota metabolites may play a role in regulating maternal-fetal immune tolerance and the pathogenesis of adverse pregnancy outcomes.Frontiers in immunology · 2026Review
- The effects of maternal dietary fiber and short-chain fatty acids on the health of offspring: a mini review.Frontiers in nutrition · 2026Review
- Maternal milk fat globule membrane enriched gutGut microbes · 2025Article
- Reduced maternal SCFAs in GDM diminish GPR43 signaling and induce offspring CAKUT.Communications biology · 2025Article
- Early-Life Prevention of Cardiovascular-Kidney-Metabolic Syndrome: The DOHaD Perspective on Resveratrol and Short-Chain Fatty Acids.Antioxidants (Basel, Switzerland) · 2025Review
- Review
- Article
- Mechanisms and therapeutic strategies of macrophages and neutrophils inducing ulcerative colitis progression.Frontiers in immunology · 2025Review
- Effects of galactooligosaccharides on maternal metabolism and the gut microbiota during pregnancy.Frontiers in microbiology · 2025Article
- Bifidobacterium species serve as key gut microbiome regulators after intervention in gestational diabetes mellitus.BMC microbiology · 2024Article
- Article
- Interactions between host and gut microbiota in gestational diabetes mellitus and their impacts on offspring.BMC microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Short-chain fatty acids (SCFAs), which are produced by gut microbiota from dietary fiber, have become candidates for gestational diabetes mellitus (GDM) treatment. However, the associations of circulating SCFAs with maternal-neonatal clinical parameters in GDM and further influences on placental immune-metabolic responses are unclear. Acetate, propionate, and butyrate were decreased in GDM during the second and third trimesters, especially in those with abnormal glucose tolerance at three "oral glucose tolerance test" time points. Butyrate was closely associated with acetate and propionate in correlation and dynamic trajectory analysis. Moreover, butyrate was negatively correlated with white blood cell counts, neutrophil counts, prepregnancy BMI, gestational weight gain per week before GDM diagnosis, and ponderal index but positively correlated with total cholesterol and low-density lipoprotein levels in all pregnancies. On the premise of reduced SCFA contents in GDM, the placental G-protein-coupled receptors 41 and 43 (GPR41/43) were decreased, and histone deacetylases (HDACs) were increased, accompanied by enhanced inflammatory responses. The metabolic status was disturbed, as evidenced by activated glycolysis in GDM. Maternal circulating acetate, propionate, and butyrate levels were associated with demographic factors in normal and GDM women. They influenced placental function and fetal development at birth through GPRs or HDACs, providing more evidence of their therapeutic capacity for GDM pregnancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.